Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Compact Benchtop System Enables Preparative Protein Purification in any Laboratory

By BiotechDaily International staff writers
Posted on 03 Dec 2013
Image: The ÄKTA start protein purification system with the Frac30 fraction collector (Photo courtesy of GE Life Sciences).
Image: The ÄKTA start protein purification system with the Frac30 fraction collector (Photo courtesy of GE Life Sciences).
A compact preparative chromatography instrument that is compatible with prepacked or user prepared columns and can be combined with fraction collectors to generate a complete protein purification system in any biotech or life sciences laboratory is now on the market.

The GE Healthcare (Chalfont St. Giles, United Kingdom) ÄKTA start is designed as a stand-alone system that combines a front-facing flow path with a user-friendly interface. The system is controlled via an intuitive touchscreen, which displays the UV curve and other run data in real-time.

ÄKTA start is compatible with all common purification techniques, including affinity and ion exchange chromatography, desalting, buffer exchange, and gel filtration. The system supports purification of tagged proteins, antibodies, untagged or native proteins, and sample clean-up applications. ÄKTA start can be operated using predefined quick-start protocols, built-in templates, or by creating custom protocols. Prepacked columns are available for common applications.

The ÄKTA start instrument can be augmented with GE Healthcare's Frac30 fraction collector for automatic protein collection, and with user-friendly UNICORN start 1.0 control software, which provides additional evaluation tools and the ability to control ÄKTA start from a computer.

Related Links:

GE Healthcare



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.